CML cells exposed to bortezomib leads to conformational changes in Bax protein, resulting in loss of mitochondrial membrane potential and leakage of cytochrome c to the cytosol. This evidence concerns the gene CYCS and chronic myelogenous leukemia, BCR-ABL1 positive.